Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease

Hye Ri Park, Jiyoon Kim, Taekeun Kim, Seonmi Jo, Miyoung Yeom, Bongjin Moon, Il Han Choo, Jaeick Lee, Eun Jeong Lim, Ki Duk Park, Sun Joon Min, Ghilsoo Nam, Gyochang Keum, Changjoon Lee, Hyunah Choo

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

In Parkinson's disease, the motor impairments are mainly caused by the death of dopaminergic neurons. Among the enzymes which are involved in the biosynthesis and catabolism of dopamine, monoamine oxidase B (MAO-B) has been a therapeutic target of Parkinson's disease. However, due to the undesirable adverse effects, development of alternative MAO-B inhibitors with greater optimal therapeutic potential towards Parkinson's disease is urgently required. In this study, we designed and synthesized the oxazolopyridine and thiazolopyridine derivatives, and biologically evaluated their inhibitory activities against MAO-B. Structure-activity relationship study revealed that the piperidino group was the best choice for the R1 amino substituent to the oxazolopyridine core structure and the activities of the oxazolopyridines with various phenyl rings were between 267.1 and 889.5 nM in IC50 values. Interestingly, by replacement of the core structure from oxazolopyrine to thiazolopyridine, the activities were significantly improved and the compound 1n with the thiazolopyridine core structure showed the most potent activity with the IC50 value of 26.5 nM. Molecular docking study showed that van der Waals interaction in the human MAO-B active site could explain the enhanced inhibitory activities of thiazolopyridine derivatives.

Original languageEnglish
Pages (from-to)5480-5487
Number of pages8
JournalBioorganic and Medicinal Chemistry
Volume21
Issue number17
DOIs
Publication statusPublished - 2013 Sep 1
Externally publishedYes

Fingerprint

Monoamine Oxidase Inhibitors
Monoamine Oxidase
Parkinson Disease
Inhibitory Concentration 50
Derivatives
Dopaminergic Neurons
Biosynthesis
Structure-Activity Relationship
Neurons
Dopamine
Catalytic Domain
Enzymes
Therapeutics

Keywords

  • MAO-B
  • Monoamine oxidase B
  • Oxazolopyridine
  • Parkinson's disease
  • Thiazolopyridine

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease. / Park, Hye Ri; Kim, Jiyoon; Kim, Taekeun; Jo, Seonmi; Yeom, Miyoung; Moon, Bongjin; Choo, Il Han; Lee, Jaeick; Lim, Eun Jeong; Park, Ki Duk; Min, Sun Joon; Nam, Ghilsoo; Keum, Gyochang; Lee, Changjoon; Choo, Hyunah.

In: Bioorganic and Medicinal Chemistry, Vol. 21, No. 17, 01.09.2013, p. 5480-5487.

Research output: Contribution to journalArticle

Park, HR, Kim, J, Kim, T, Jo, S, Yeom, M, Moon, B, Choo, IH, Lee, J, Lim, EJ, Park, KD, Min, SJ, Nam, G, Keum, G, Lee, C & Choo, H 2013, 'Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease', Bioorganic and Medicinal Chemistry, vol. 21, no. 17, pp. 5480-5487. https://doi.org/10.1016/j.bmc.2013.05.066
Park, Hye Ri ; Kim, Jiyoon ; Kim, Taekeun ; Jo, Seonmi ; Yeom, Miyoung ; Moon, Bongjin ; Choo, Il Han ; Lee, Jaeick ; Lim, Eun Jeong ; Park, Ki Duk ; Min, Sun Joon ; Nam, Ghilsoo ; Keum, Gyochang ; Lee, Changjoon ; Choo, Hyunah. / Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease. In: Bioorganic and Medicinal Chemistry. 2013 ; Vol. 21, No. 17. pp. 5480-5487.
@article{e1ff5958b77b4eebb3f57068ceef0987,
title = "Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease",
abstract = "In Parkinson's disease, the motor impairments are mainly caused by the death of dopaminergic neurons. Among the enzymes which are involved in the biosynthesis and catabolism of dopamine, monoamine oxidase B (MAO-B) has been a therapeutic target of Parkinson's disease. However, due to the undesirable adverse effects, development of alternative MAO-B inhibitors with greater optimal therapeutic potential towards Parkinson's disease is urgently required. In this study, we designed and synthesized the oxazolopyridine and thiazolopyridine derivatives, and biologically evaluated their inhibitory activities against MAO-B. Structure-activity relationship study revealed that the piperidino group was the best choice for the R1 amino substituent to the oxazolopyridine core structure and the activities of the oxazolopyridines with various phenyl rings were between 267.1 and 889.5 nM in IC50 values. Interestingly, by replacement of the core structure from oxazolopyrine to thiazolopyridine, the activities were significantly improved and the compound 1n with the thiazolopyridine core structure showed the most potent activity with the IC50 value of 26.5 nM. Molecular docking study showed that van der Waals interaction in the human MAO-B active site could explain the enhanced inhibitory activities of thiazolopyridine derivatives.",
keywords = "MAO-B, Monoamine oxidase B, Oxazolopyridine, Parkinson's disease, Thiazolopyridine",
author = "Park, {Hye Ri} and Jiyoon Kim and Taekeun Kim and Seonmi Jo and Miyoung Yeom and Bongjin Moon and Choo, {Il Han} and Jaeick Lee and Lim, {Eun Jeong} and Park, {Ki Duk} and Min, {Sun Joon} and Ghilsoo Nam and Gyochang Keum and Changjoon Lee and Hyunah Choo",
year = "2013",
month = "9",
day = "1",
doi = "10.1016/j.bmc.2013.05.066",
language = "English",
volume = "21",
pages = "5480--5487",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "17",

}

TY - JOUR

T1 - Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease

AU - Park, Hye Ri

AU - Kim, Jiyoon

AU - Kim, Taekeun

AU - Jo, Seonmi

AU - Yeom, Miyoung

AU - Moon, Bongjin

AU - Choo, Il Han

AU - Lee, Jaeick

AU - Lim, Eun Jeong

AU - Park, Ki Duk

AU - Min, Sun Joon

AU - Nam, Ghilsoo

AU - Keum, Gyochang

AU - Lee, Changjoon

AU - Choo, Hyunah

PY - 2013/9/1

Y1 - 2013/9/1

N2 - In Parkinson's disease, the motor impairments are mainly caused by the death of dopaminergic neurons. Among the enzymes which are involved in the biosynthesis and catabolism of dopamine, monoamine oxidase B (MAO-B) has been a therapeutic target of Parkinson's disease. However, due to the undesirable adverse effects, development of alternative MAO-B inhibitors with greater optimal therapeutic potential towards Parkinson's disease is urgently required. In this study, we designed and synthesized the oxazolopyridine and thiazolopyridine derivatives, and biologically evaluated their inhibitory activities against MAO-B. Structure-activity relationship study revealed that the piperidino group was the best choice for the R1 amino substituent to the oxazolopyridine core structure and the activities of the oxazolopyridines with various phenyl rings were between 267.1 and 889.5 nM in IC50 values. Interestingly, by replacement of the core structure from oxazolopyrine to thiazolopyridine, the activities were significantly improved and the compound 1n with the thiazolopyridine core structure showed the most potent activity with the IC50 value of 26.5 nM. Molecular docking study showed that van der Waals interaction in the human MAO-B active site could explain the enhanced inhibitory activities of thiazolopyridine derivatives.

AB - In Parkinson's disease, the motor impairments are mainly caused by the death of dopaminergic neurons. Among the enzymes which are involved in the biosynthesis and catabolism of dopamine, monoamine oxidase B (MAO-B) has been a therapeutic target of Parkinson's disease. However, due to the undesirable adverse effects, development of alternative MAO-B inhibitors with greater optimal therapeutic potential towards Parkinson's disease is urgently required. In this study, we designed and synthesized the oxazolopyridine and thiazolopyridine derivatives, and biologically evaluated their inhibitory activities against MAO-B. Structure-activity relationship study revealed that the piperidino group was the best choice for the R1 amino substituent to the oxazolopyridine core structure and the activities of the oxazolopyridines with various phenyl rings were between 267.1 and 889.5 nM in IC50 values. Interestingly, by replacement of the core structure from oxazolopyrine to thiazolopyridine, the activities were significantly improved and the compound 1n with the thiazolopyridine core structure showed the most potent activity with the IC50 value of 26.5 nM. Molecular docking study showed that van der Waals interaction in the human MAO-B active site could explain the enhanced inhibitory activities of thiazolopyridine derivatives.

KW - MAO-B

KW - Monoamine oxidase B

KW - Oxazolopyridine

KW - Parkinson's disease

KW - Thiazolopyridine

UR - http://www.scopus.com/inward/record.url?scp=84881376962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881376962&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2013.05.066

DO - 10.1016/j.bmc.2013.05.066

M3 - Article

VL - 21

SP - 5480

EP - 5487

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 17

ER -